Sabril is dangerous. One third of people who take it will have permanent vision loss. It would never have been approved if Acthar had been approved for IS at that time.
Questcor has been upfront with investors about the challenges ahead. Virtually every news release outlines those challenges and the steps the company is taking to meet them. In addition, investors have access to all kinds of research on companies they may want to invest in. So if it's the investors you are worried about, don't be. And thanks for your concern.